Enlivex Therapeutics (NASDAQ:ENLV) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Enlivex Therapeutics (NASDAQ:ENLV) from a strong sell rating to a hold rating in a research report report published on Saturday morning.

Other analysts also recently issued research reports about the stock. HC Wainwright upped their price target on shares of Enlivex Therapeutics from $7.00 to $13.00 and gave the stock a “buy” rating in a report on Monday, January 12th. D Boral Capital downgraded shares of Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enlivex Therapeutics in a report on Monday, December 29th. Finally, D. Boral Capital reiterated a “hold” rating on shares of Enlivex Therapeutics in a research note on Monday, November 24th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $13.00.

Enlivex Therapeutics Stock Performance

Shares of NASDAQ ENLV opened at $0.94 on Friday. Enlivex Therapeutics has a 52 week low of $0.66 and a 52 week high of $2.10. The stock has a market capitalization of $223.14 million, a P/E ratio of -1.71 and a beta of 1.52. The stock’s fifty day moving average is $0.91 and its 200 day moving average is $1.07.

Enlivex Therapeutics (NASDAQ:ENLV) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.03. Equities research analysts forecast that Enlivex Therapeutics will post -0.7 earnings per share for the current year.

Hedge Funds Weigh In On Enlivex Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ENLV. Citizens Financial Group Inc. RI acquired a new stake in shares of Enlivex Therapeutics during the third quarter valued at about $241,000. Jane Street Group LLC increased its stake in shares of Enlivex Therapeutics by 527.4% in the first quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock valued at $78,000 after buying an additional 67,886 shares during the period. Finally, Susquehanna International Group LLP acquired a new position in shares of Enlivex Therapeutics in the third quarter valued at approximately $57,000. Institutional investors and hedge funds own 1.02% of the company’s stock.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.